Over my 30 years in the drug development industry, I have had the privilege to work with a variety of cell and gene therapies. Much of that work has been on the regulatory margins, navigating the new through what is permissible to what is possible [1]. Personalised genomic therapies encompass a range of interventions designed to target specific genetic alterations in individual patients or small patient populations; examples include antisense oligonucleotides (ASOs), gene editing technologies such as CRISPR, and messenger RNA (mRNA)-based therapeutics. Ultra-rare diseases, though individually affecting minuscule patient populations (often fewer than 30 patients globally), collectively represent a substantial public health burden, with most lacking any approved therapeutic options [2].
Historically, cell and gene therapies have faced a difficult pathway to regulatory acceptance due to small patient populations, long development timelines and regulatory caution, given their long-lasting effects. However, we may be about to see a seismic shift in the regulatory landscape with the introduction of the FDA's Plausible Mechanism Framework for Personalised Genomic and Ultra-Rare Disease Therapies [3]
The conventional drug development paradigm, predicated on large-scale randomised controlled trials (RCTs) with homogeneous patient populations, has proven fundamentally incompatible with the realities of ultra-rare genetic diseases. For conditions affecting a handful of patients worldwide, traditional statistical power calculations become absurdities, and the economic imperatives that drive pharmaceutical investment evaporate. The administration of the world’s first personalised CRISPR treatment to Baby KJ, an infant with carbamoyl-phosphate synthetase 1 (CPS1) deficiency, a condition affecting approximately one in 1.3 million people, catalysed regulatory recognition that existing pathways were failing patients with ultra-rare diseases [2]. The successful development and administration of a custom mRNA-encoded base editor targeting his specific mutation, accomplished in just 7 months through an unprecedented collaboration between academia and industry, demonstrated both the scientific feasibility of bespoke genomic interventions and the regulatory flexibility required to enable them [4,5]. The FDA reviewed and cleared the single-patient expanded-access request within 1 week, demonstrating regulatory agility that the framework now seeks to systematise [5,6].
In November 2025, senior FDA leaders proposed the Plausible Mechanism Pathway, subsequently elaborated in draft guidance released in February 2026, representing the agency's most significant regulatory innovation in personalised medicine in a quarter-century [5,7]. Let’s examine the framework's provisions, scientific underpinnings, and implications for the future of ultra-rare disease therapeutic development.
The New FDA Guidelines: Structure and Substance
The Plausible Mechanism Framework, developed jointly by the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), establishes a structured regulatory pathway for individualized therapies when traditional clinical trial designs are impractical due to extreme patient scarcity [7]. Unlike previous guidance documents, which incrementally addressed rare disease challenges, this framework fundamentally reconceptualises the evidentiary standards for approval.
Core Requirements
To qualify for the pathway, sponsors must satisfy five evidentiary pillars.
- Developers must precisely identify the specific genetic, cellular, or molecular abnormality causing the disease, a requirement that restricts the pathway to conditions with well-characterised pathophysiology and excludes those defined solely by clinical phenotype or unclear genome-wide associations [5].
- Sponsors must demonstrate that their therapeutic intervention targets this root cause or the proximate biological pathway, establishing mechanistic plausibility [7].
- Evidence of successful target engagement must be provided, confirming that the therapy has effectively bound, edited, or otherwise modified its intended target. In the Baby KJ case, this was supported by mouse model data demonstrating successful editing in 42% of liver cells, though the FDA has indicated it will accept alternative evidence when human biopsies are clinically inappropriate [5,6].
- Sponsors must integrate high-quality, well-characterised natural history data from untreated patients to establish a comparative baseline, an expectation that, while not new, is applied with greater flexibility regarding data sources [2,7].
- The therapy must demonstrate improved clinical outcomes, with data sufficiently robust to exclude regression to the mean [6].
Innovations
The guidance introduces several procedural innovations that distinguish it from previous regulatory approaches. Most significantly, it permits the use of master protocols and platform-based development strategies, recognising that a single technological platform, such as CRISPR-Cas9 or mRNA therapeutics, may be adapted to target multiple mutations within the same gene [4]. Once a sponsor demonstrates that a platform successfully treats several consecutive patients with different customized therapies, the FDA may grant marketing authorisation for the platform, allowing its application to additional mutations without repeating full clinical development programs [6,8].
Post-marketing, sponsors are required to collect real-world evidence to confirm long-term efficacy and to monitor off-target effects or other unforeseen safety concerns [5,6]. This represents a deliberate trade-off: accepting greater uncertainty at approval in exchange for more rigorous post-market surveillance, a calculation that acknowledges the impossibility of generating traditional pre-market evidence packages for ultra-rare diseases.
Comparison with Previous Guidance
Previous FDA guidance on drug development in rare diseases remained anchored in conventional evidentiary hierarchies, although progressively accommodating smaller datasets and greater reliance on natural history controls, [9]. Documents addressing pre-IND meetings for rare diseases, natural history study design, and evidence for replacement therapies in slowly progressive disorders all presupposed the eventual possibility of adequate sample sizes [9]. The Plausible Mechanism Framework abandons this presupposition entirely accepting that, for some diseases, the entire patient population will never exceed single digits.
The 2024 guidance on individualised ASO drug products began moving in this direction, addressing administrative, nonclinical, clinical, and chemistry, manufacturing, and controls (CMC) considerations for therapies developed for single patients [10]. The Plausible Mechanism Framework extends and generalises this approach beyond ASOs to encompass the full range of genomic interventions, including genome editing and mRNA-based therapeutics [7].
Scientific and Regulatory Context
Personalised genomic approaches challenge traditional regulatory pathways in fundamental ways that extend beyond sample size considerations. The underlying therapeutic platform, whether CRISPR-Cas9, zinc finger nucleases, or antisense technology, may remain constant across applications, while the targeting mechanism (guide RNA, antisense sequence) varies with each patient's mutation [7]. This creates regulatory ambiguity regarding whether each application constitutes a new drug requiring independent approval or a variation on an approved platform.
The framework's platform-based approach addresses this ambiguity but raises equally complex questions about the boundaries of what constitutes "the same technology." As Sadik Kassim of Danaher Corporation, part of the team involved in manufacturing Baby KJ’s bespoke gene therapy, has noted, the guidance leaves undefined whether a platform demonstrated effective for one disease can be extrapolated to a related but distinct disorder, and how information sharing between institutions might facilitate such extrapolation [2].
Clinical trial design for ultra-rare diseases has long grappled with methodological challenges that the new framework acknowledges but does not fully resolve. The FDA's acceptance of patients as their own controls, comparison with natural history data, and reliance on small case series represent pragmatic accommodations to feasibility constraints [6,7]. However, these designs remain vulnerable to confounding, regression to the mean, and placebo effects, threats that the framework attempts to mitigate through requirements for robust effect sizes and biological plausibility but cannot eliminate entirely.
Critical Appraisal: Strengths and Limitations
Strengths of the Framework
The Plausible Mechanism Framework represents a meaningful and potentially transformative step forward in facilitating therapies for ultra-rare diseases. Its primary strength lies in its explicit recognition that traditional evidentiary standards, however appropriate for common diseases, become nonsensical when applied to conditions affecting handfuls of patients. By articulating a coherent alternative framework, the FDA provides regulatory predictability that has been conspicuously absent, potentially encouraging investment and innovation in spaces previously deemed commercially nonviable [2].
The framework's flexibility regarding evidence sources aligns regulatory expectations with scientific realities: accepting non-animal models when human biopsies are infeasible, permitting single-arm studies with natural history comparators, and embracing real-world evidence for post-marketing confirmation [6,7]. This flexibility extends to manufacturing, where the guidance acknowledges that bespoke therapies cannot conform to the standardised production paradigms that govern conventional pharmaceuticals [2].
The platform-based approval concept represents a particularly elegant solution to the scalability challenge. By enabling developers to establish the safety and efficacy of a technological platform and then apply it to multiple mutations without repeating full development programs, the framework creates economic efficiencies that could make ultra-rare disease therapies commercially sustainable [8]. The Alliance for mRNA Medicines has welcomed this approach, noting its potential to transform the economics of personalised genomic medicine [4].
Limitations
Despite the possible strengths, the framework leaves significant uncertainties unresolved. Manufacturing expectations remain ambiguous, particularly regarding whether developers should continue producing personalised therapies through the same collaborative, at-risk models that enabled Baby KJ's treatment or whether the FDA envisions alternative pathways [2]. The guidance's silence on manufacturing standardisation creates uncertainty for developers attempting to design scalable production systems.
The definition of platform technology, while central to the framework's efficiency rationale, lacks precision. As Kassim observes, the guidance does not clarify what constitutes sufficient similarity to qualify for platform-based extrapolation, nor does it address how comparability might be demonstrated across different institutions or manufacturing sites [2]. This ambiguity could either stifle innovation through regulatory uncertainty or, conversely, create opportunities for regulatory arbitrage if interpreted too liberally.
The framework's reliance on natural history data, while necessary, assumes the existence of high-quality natural history studies for diseases so rare that their natural history may never have been systematically characterised. Previous FDA guidance has emphasised the importance of natural history studies for rare diseases, but the practical reality is that for ultra-rare conditions, such data may be fragmentary or non-existent [7,9].
Perhaps most significantly, the framework does not address the economic sustainability of ultra-rare disease therapy development. As Kassim notes, industry investment is incentivised by reimbursement, not by publications or grant funding, yet the guidance offers no clarity on how developers, manufacturers, and investigators will be compensated [2]. Without viable reimbursement pathways, regulatory approval may prove an empty victory.
Implications for Industry
For pharmaceutical and biotechnology companies, the Plausible Mechanism Framework creates both opportunities and strategic dilemmas. The pathway potentially opens new markets in ultra-rare diseases that were previously economically unattractive, particularly for platform technologies that can be applied across multiple mutations [6,7]. Companies with established genomic platforms, CRISPR therapeutics, mRNA technologies, antisense oligonucleotides, may find themselves with valuable assets that can now reach patients with minimal incremental development costs.
However, the framework also challenges conventional business models. The traditional approach of developing a single drug for a large population and recouping investment through blockbuster sales does not translate to markets measured in dozens of patients. Companies must develop new economic models, potentially including high per-patient pricing, public-private partnerships, or vertically integrated platforms that aggregate multiple ultra-rare indications [2].
Clinical research organisations face evolving demands as trial designs shift from large RCTs to small single-arm studies with natural history comparators. Expertise in natural history study design, real-world evidence collection, and regulatory strategy for novel pathways will become increasingly valuable [7,9].
Academic developers, who have historically driven innovation in ultra-rare diseases, may find the framework particularly enabling. The Baby KJ case demonstrated that academic-industry collaborations can successfully navigate regulatory pathways when traditional development models fail [2,4]. The framework's explicit articulation of evidentiary expectations could empower academic investigators to pursue regulatory approval independently, though manufacturing and commercialisation challenges may still require industry partnerships [2].
Several areas require further FDA clarification. Standardisation of genomic endpoints across platform applications would facilitate extrapolation and reduce regulatory uncertainty. Harmonisation with international regulatory frameworks remains unaddressed, potentially creating challenges for global development programs. And the data requirements for platform extrapolation, what evidence suffices to demonstrate that a new application falls within an approved platform, require more precise definition [2].
Case Context and Policy Drivers
This Baby KJ case was not unprecedented. In 2018, researchers developed a bespoke ASO treatment for a child with Batten disease, and similar approaches have since been replicated [6]. However, each such effort required bespoke regulatory navigation, with no established pathway for generalising learnings across cases. The Plausible Mechanism Framework addresses this gap by creating a structured approach that can accommodate and learn from each successive application.
Geopolitical pressures have likely accelerated this regulatory evolution. The framework's announcement emphasised maintaining American leadership in biotechnology and ensuring that regulatory barriers do not drive innovation overseas [7,8]. The involvement of Health and Human Services leadership in promoting the framework reflects administration priorities around deregulation and accelerated access to innovative therapies [7]. Whether similar pressures will drive harmonisation with European or other international regulators remains to be seen.
Conclusion and Recommendations
The FDA's Plausible Mechanism Framework represents a watershed moment in the regulation of personalised genomic therapies for ultra-rare diseases. By explicitly articulating a pathway that abandons traditional RCT requirements in favour of biologically plausible, mechanistically evidenced approaches, the agency has aligned regulatory expectations with scientific reality. The framework's embrace of platform-based approvals, flexible evidence standards, and post-marketing real-world evidence creates a coherent structure that could finally unlock therapeutic development for conditions previously deemed commercially impossible.
For regulators, the priority should be iterative refinement based on early experience. The framework's draft guidance provides an opportunity for stakeholder input that should be seized to address remaining uncertainties [2]. For industry, the framework invites strategic experimentation with platform-based business models and collaborative development approaches. For academic developers, it offers a potential pathway to regulatory approval independent of traditional pharmaceutical partnerships.
The framework is both sensible and safe, provided its accommodations to ultra-rare disease realities are not misinterpreted as generalised relaxations of evidentiary standards for common diseases. Its focus on well-characterised molecular pathophysiology, requirement for demonstrated target engagement, and insistence on robust clinical effect sizes maintain scientific rigour while acknowledging feasibility constraints. For patients with ultra-rare diseases and their families, for whom waiting for traditional evidence generation means watching their children die, this framework offers something unprecedented: a regulatory pathway that moves at the speed of science rather than the speed of bureaucracy.
References
- Cook J. The Rise of Personalised Gene Therapy: a 30-year perspective. 2026. https://niche.org.uk/small-molecules-to-gene-therapy
- Pharmaceutical Technology. Impacts of FDA's plausible mechanism framework for ultra-rare disease therapies. 2026 Feb 24 [cited 2026 Feb 27]. Available from: https://www.pharmtech.com/view/impacts-of-fda-s-plausible-mechanism-framework-for-ultra-rare-disease-therapies
- Food and Drug Administration (FDA). Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause [Internet]. Silver Spring (MD): FDA; 2026 Feb 23 [cited 2026 Mar 12]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific
- Alliance for mRNA Medicines. Alliance for mRNA Medicines welcomes new FDA framework to accelerate development of personalized gene therapies. 2025 Nov 13 [cited 2026 Feb 27]. Available from: https://mrnamedicines.org/alliance-for-mrna-medicines-welcomes-new-fda-framework-to-accelerate-development-of-personalized-gene-therapies/
- Regulatory Affairs Professionals Society. FDA leaders propose new 'plausible mechanism' pathway for bespoke medicines. 2025 Nov 13 [cited 2026 Feb 27]. Available from: https://www.raps.org/news-and-articles/news-articles/2025/11/fda-leaders-propose-new-%e2%80%98plausible-mechanism-pathw
- Xtalks. FDA launches "plausible mechanism pathway" to deliver individualized, bespoke therapies to patients faster. 2025 Nov 17 [cited 2026 Feb 27]. Available from: https://xtalks.com/fda-launches-plausible-mechanism-pathway-to-deliver-individualized-bespoke-therapies-to-patients-faster-4491/
- Pharmaceutical Technology. Impacts of FDA's plausible mechanism framework for ultra-rare disease therapies. 2026 Feb 24 [cited 2026 Feb 27]. Available from: https://www.pharmtech.com/view/impacts-of-fda-s-plausible-mechanism-framework-for-ultra-rare-disease-therapies
- 環球生技月刊. FDA公布「合理機制途徑」罕病客製基因療法加速上市. 2026 Feb 24 [cited 2026 Feb 27]. Available from: https://news.gbimonthly.com/tw/article/show.php?num=83900&range=web
- oneAMYLOIDOSISvoice. Guidance documents for rare disease drug development. 2024 [cited 2026 Feb 27]. Available from: https://oneamyloidosisvoice.com/rcuratenew/guidance-documents-rare-disease-drug-development
- MMS Holdings. New FDA guidance for ultra rare disease: support and drug development. 2024 Sep 9 [cited 2026 Feb 27]. Available from: https://quality.mmsholdings.com/perspectives/new-fda-guidance-to-support-ultra-rare-disease-drug-development/
